{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+2+-+Placebo&page=48",
    "query": {
      "intervention": "Intervention 2 - Placebo",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 1496,
    "total_pages": 150,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+2+-+Placebo&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intervention+2+-+Placebo&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T21:56:04.875Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03725059",
      "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab (K)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (P)",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel (X)",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin (A)",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin (E)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide (C)",
          "type": "DRUG"
        },
        {
          "name": "Endocrine therapy",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1240,
      "start_date": "2018-12-27",
      "completion_date": "2031-01-24",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 45,
      "location_summary": "Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03725059"
    },
    {
      "nct_id": "NCT01205503",
      "title": "Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mara Chambers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-02-24",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205503"
    },
    {
      "nct_id": "NCT06141473",
      "title": "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Frexalimab",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        },
        {
          "name": "MRI contrast-enhancing agents",
          "type": "DRUG"
        },
        {
          "name": "Cholestyramine",
          "type": "DRUG"
        },
        {
          "name": "Activated charcoal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1655,
      "start_date": "2023-12-13",
      "completion_date": "2027-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 99,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06141473"
    },
    {
      "nct_id": "NCT02101970",
      "title": "Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Omega-3 Fatty Acids",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Capsule",
          "type": "OTHER"
        },
        {
          "name": "Diet and Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Carol Fabian, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 70 Years · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2014-03",
      "completion_date": "2018-08-27",
      "has_results": false,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02101970"
    },
    {
      "nct_id": "NCT02096965",
      "title": "Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nephrolithiasis, Calcium Oxalate",
        "Nephrolithiasis, Calcium Phosphate"
      ],
      "interventions": [
        {
          "name": "Tolvaptan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-03-30",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096965"
    },
    {
      "nct_id": "NCT00116207",
      "title": "An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Autonomic Neuropathy"
      ],
      "interventions": [
        {
          "name": "ORAL ANTIOXIDANT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2000-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2016-07-29",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116207"
    },
    {
      "nct_id": "NCT07779967",
      "title": "Alcohol, Breast Cancer, and Metabolism",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Drinking",
        "Ethanol Intoxication",
        "Breastfeeding"
      ],
      "interventions": [
        {
          "name": "Low-alcohol level exposure",
          "type": "OTHER"
        },
        {
          "name": "Breast-pumping time",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Illinois at Urbana-Champaign",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 45 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2026-09-03",
      "completion_date": "2032-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "Urbana, Illinois",
      "locations": [
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07779967"
    },
    {
      "nct_id": "NCT03963895",
      "title": "Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "AB002 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "AB002 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aronora, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-07-03",
      "completion_date": "2020-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-03-07",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03963895"
    },
    {
      "nct_id": "NCT03077919",
      "title": "Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PostTraumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "Sham treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RTI International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2016-05-25",
      "completion_date": "2018-06-09",
      "has_results": true,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 2,
      "location_summary": "Honolulu, Hawaii • Fort Bragg, North Carolina",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Fort Bragg",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03077919"
    },
    {
      "nct_id": "NCT00422487",
      "title": "Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MBX-2044",
          "type": "DRUG"
        },
        {
          "name": "Placebo for MBX-2044",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-10",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2015-05-01",
      "last_synced_at": "2026-11-18T21:56:04.875Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00422487"
    }
  ]
}